Kazia Therapeutics Limited
KZIA
$3.82
-$0.11-2.80%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 760.50K | 758.90K | -- | -- | -- |
| Total Other Revenue | 57.00K | 56.90K | 0.00 | 0.00 | 300.00 |
| Total Revenue | 817.50K | 815.80K | 0.00 | 0.00 | 300.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 817.50K | 815.80K | 0.00 | 0.00 | 300.00 |
| SG&A Expenses | 2.97M | 2.96M | 1.48M | 1.49M | 1.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.27M | 7.25M | 2.89M | 2.91M | 3.51M |
| Operating Income | -6.45M | -6.44M | -2.89M | -2.91M | -3.51M |
| Income Before Tax | -5.96M | -5.95M | -2.92M | -2.93M | -2.34M |
| Income Tax Expenses | -44.60K | -44.50K | -44.20K | -44.40K | -45.20K |
| Earnings from Continuing Operations | -5.92M | -5.90M | -2.88M | -2.89M | -2.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.92M | -5.90M | -2.88M | -2.89M | -2.30M |
| EBIT | -6.45M | -6.44M | -2.89M | -2.91M | -3.51M |
| EBITDA | -6.14M | -6.13M | -2.59M | -2.60M | -3.20M |
| EPS Basic | -5.14K | -5.13K | -3.00K | -3.01K | -2.58K |
| Normalized Basic EPS | -6.58 | -6.57 | -3.73 | -3.75 | -4.91 |
| EPS Diluted | -5.14K | -5.13K | -3.00K | -3.01K | -2.58K |
| Normalized Diluted EPS | -6.58 | -6.57 | -3.73 | -3.75 | -4.91 |
| Average Basic Shares Outstanding | 575.10K | 575.10K | 479.60K | 479.60K | 445.80K |
| Average Diluted Shares Outstanding | 1.10K | 1.10K | 900.00 | 900.00 | 800.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |